Core Viewpoint - HUTCHMED has initiated a registrational Phase III clinical trial for HMPL-760 in combination with R-GemOx for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in China, with the first patient dosed on March 20, 2026 [1]. Group 1: Clinical Trial Details - The Phase III trial is randomized, double-blind, and positive controlled, evaluating the efficacy, safety, and pharmacokinetics of HMPL-760 combined with R-GemOx versus placebo with R-GemOx in DLBCL patients who are relapsed or refractory after prior treatments [3]. - The trial aims to enroll approximately 240 patients and is led by Professor Weili Zhao from Ruijin Hospital, Shanghai [4]. Group 2: Background on DLBCL and HMPL-760 - DLBCL is the most common form of aggressive non-Hodgkin lymphoma, accounting for about 40% of all NHL cases in China, with an estimated 81,000 new cases diagnosed in 2022 [2]. - HMPL-760 is a third-generation, non-covalent BTK inhibitor that has shown promising results in a Phase II study, demonstrating improvements in overall response rate, complete response rate, progression-free survival, and overall survival compared to R-GemOx alone [5]. Group 3: Company Overview - HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [7]. - The company retains all rights to HMPL-760 worldwide, indicating its commitment to advancing this investigational therapy [6].